Post ERCP Pancreatitis Post ERCP Abdominal pain score Risk factor for Post ERCP Pancreatitis ERCP Pancreatitis Dynastat Parecoxib sodium
Conditions
Interventions
COX-2 inhibitor administered parenterally. It is a prodrug that is rapidly hydrolysed in vivo to its active form, valdecoxib. Its metabolite in liver and excrete mainly in urine. It has been approved
Experimental Drug,Placebo Comparator No treatment
Parecoxib sodium,Normal saline
Sponsors
MNRH Institution Review board
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients undergoing ERCP at Maharat Nakhon Ratchasima Hospital Age more than 20 years
Exclusion criteria
Exclusion criteria: Hypersensitivity/Contraindication to parecoxib, NSAIDs, or sulfonamide Active/Recent Gastrointestinal bleeding or Recent Peptic ulcer disease within 4 weeks Renal dysfunction (Cr > 1.5 mg/dL) History of Myocardial infarction ECOG 4 NSAIDs use during preceding week (ASA 325 mg daily or less) Acute pancreatitis less than 2 weeks before ERCP History of Bilioenteric bypass History of chronic pancreatitis Pregnancy or Breast feeding Patient with HIV infection Refused to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post ERCP Pancreatitis before patient discharge from admission Criteria for diagnosis Pancreatitis as consensus criteria | — |
Secondary
| Measure | Time frame |
|---|---|
| Post operative pain score when patient arrived at inpatient department after ERCP Abdominal pain score ,Risk factor for Post ERCP Pancreatitis within 3 months after end of study Compare incidence of Post ERCP Pancreatitis between Parecoxib and placebo | — |
Countries
Thailand
Contacts
Public ContactAekaritch Nattigon
Maharat Nakorn Ratchasima Hospita
Outcome results
None listed